Physician profile
Kenneth Oforeh
NPI 1689284002
$1,257.26
in general payments reported to CMS, 2019-2025
11 companies · $102 in 2025
The $102 reported for 2025 was less than what a typical Behavioral Neurology & Neuropsychiatry provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $410 · 2024: $746 · 2025: $102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,257.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $218.50 | 2023-2024 | Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $178.13 | 2024 | Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $151.67 | 2024 | Austedo Xr, Uzedy |
| Abbvie INC. | $129.87 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $105.12 | 2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $92.52 | 2023 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $90.32 | 2024 | Ingrezza |
| Bioxcel Therapeutics, INC. | $85.76 | 2023-2024 | Igalmi |
| Alkermes, INC. | $73.73 | 2024 | Aristada, Lybalvi, Vivitrol |
| Kyowa Kirin, INC. | $72.00 | 2025 | |
| Indivior INC. | $59.64 | 2023 | Perseris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Oforeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.